ArticleRegulatory toxicology and pharmacology : RTP2019
Genetic toxicology in silico protocol.
Article in Regulatory toxicology and pharmacology : RTP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Animal reuse in safety assessment studies: a review of current practices, challenges and 3Rs opportunities.Frontiers in toxicology · 2026Review
- A pragmatic workflow for integrating large language models into toxicological risk assessment.Frontiers in toxicology · 2026Article
- Interpretation of in vitro concentration-response data for risk assessment and regulatory decision-making: Report from the 2022 IWGT quantitative analysis expert working group meeting.Environmental and molecular mutagenesis · 2025Review
- Development, Use, and Validation of (Q)SARs for Predicting Genotoxicity and Carcinogenicity: Experiences from Italian National Institute of Health Activities.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods.Pharmacological reviews · 2024Review
- Matrine and Oxymatrine: evaluating the gene mutation potential using in silico tools and the bacterial reverse mutation assay (Ames test).Mutagenesis · 2024Article
- Big data and its impact on the 3Rs: a home cage monitoring oriented review.Frontiers in big data · 2024Review
- Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.Frontiers in toxicology · 2024Article
- MicotoXilico: An Interactive Database to Predict Mutagenicity, Genotoxicity, and Carcinogenicity of Mycotoxins.Toxins · 2023Article
- Article
- Principles and Procedures for Assessment of Acute Toxicity IncorporatingComputational toxicology (Amsterdam, Netherlands) · 2022Article
- Current status and future directions for a neurotoxicity hazard assessment framework that integratesComputational toxicology (Amsterdam, Netherlands) · 2022Article
- Evaluating Confidence in Toxicity Assessments Based on Experimental Data andComputational toxicology (Amsterdam, Netherlands) · 2022Article
- Implementation ofComputational toxicology (Amsterdam, Netherlands) · 2022Article
- Implementation of In Silico Toxicology Protocols in Leadscope.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Integrating publicly available information to screen potential candidates for chemical prioritization under the Toxic Substances Control Act: A proof of concept case study using genotoxicity and carcinogenicity.Computational toxicology (Amsterdam, Netherlands) · 2021Article
- Article
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
74 authors.
Funding
Abstract
In silico toxicology (IST) approaches to rapidly assess chemical hazard, and usage of such methods is increasing in all applications but especially for regulatory submissions, such as for assessing chemicals under REACH as well as the ICH M7 guideline for drug impurities. There are a number of obstacles to performing an IST assessment, including uncertainty in how such an assessment and associated expert review should be performed or what is fit for purpose, as well as a lack of confidence that the results will be accepted by colleagues, collaborators and regulatory authorities. To address this, a project to develop a series of IST protocols for different hazard endpoints has been initiated and this paper describes the genetic toxicity in silico (GIST) protocol. The protocol outlines a hazard assessment framework including key effects/mechanisms and their relationships to endpoints such as gene mutation and clastogenicity. IST models and data are reviewed that support the assessment of these effects/mechanisms along with defined approaches for combining the information and evaluating the confidence in the assessment. This protocol has been developed through a consortium of toxicologists, computational scientists, and regulatory scientists across several industries to support the implementation and acceptance of in silico approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.